SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System

Lancet Diabetes Endocrinol. 2017 Sep;5(9):680-681. doi: 10.1016/S2213-8587(17)30257-7. Epub 2017 Jul 18.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amputation / statistics & numerical data*
  • Canagliflozin / adverse effects*
  • Cardiovascular Diseases / etiology
  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / surgery*
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Risk Factors
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors*
  • United States
  • United States Food and Drug Administration

Substances

  • Hypoglycemic Agents
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin